Journal
CANCER CELL
Volume 27, Issue 4, Pages 429-431Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2015.03.013
Keywords
-
Categories
Funding
- Cancer Research UK [15703] Funding Source: researchfish
Ask authors/readers for more resources
Perhaps the most pressing need in cancer therapeutics is to understand drug resistance. In this issue of Cancer Cell, Hirata and colleagues show that melanoma-associated fibroblasts can drive resistance to the BRAF inhibitor PLX4720 by stimulating matrix production/remodeling, and, consequently, survival signaling in melanoma cells via beta 1-integrin, Src, and FAK.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available